Treatment
Baricitinib (LY3009104) clinical trials
We’re tracking 4 recruiting studies that include Baricitinib (LY3009104), each written for real people, not researchers, below.
Recruiting studies
- NCT07222137RecruitingPhase 3
Baricitinib to delay type 1 diabetes in at-risk people
This trial tests if baricitinib, a pill that calms the immune system, can slow down or delay the onset of type 1 diabetes in children and adults who are at high risk. It is for people whose blood sugar is already starting to rise but who do not yet need insulin.
Tallahassee, FloridaAges 1–35 - NCT07222332RecruitingPhase 3
Baricitinib for new type 1 diabetes to save insulin-making cells
This trial tests if baricitinib, a pill that calms the immune system, can protect the remaining insulin-making cells in people newly diagnosed with type 1 diabetes. If it works, you might keep making some of your own insulin longer.
Aurora, ColoradoAges 1–35 - NCT05723198RecruitingPhase 3
Baricitinib for severe childhood hair loss from alopecia areata
This trial tests whether baricitinib can improve severe alopecia areata (patchy, autoimmune hair loss) in children and teens. It’s meant for people who have had long-lasting, severe hair loss and have tried other treatments without enough benefit.
Birmingham, AlabamaAges 6–17 - NCT06687551RecruitingPhase 4
Testing lower doses of JAK inhibitors for rheumatoid arthritis
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Toulouse, OccitanieAges 18–65
What Baricitinib (LY3009104) is being studied for
Conditions with recruiting Baricitinib (LY3009104) studies.
Common questions
- Are there clinical trials studying Baricitinib (LY3009104)?
- Yes. Clin2 currently lists 4 recruiting studies that include Baricitinib (LY3009104), drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Baricitinib (LY3009104) trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Baricitinib (LY3009104) an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Baricitinib (LY3009104) or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.